Evaluation of Genetic Polymorphism of Leishmania (V.) braziliensis Isolates Obtained from the Same Patient before and after Therapeutic Failure or Reactivation of Cutaneous Lesions
Table 1
Data from 15 patients with ATL with failure to treatment or reactivation.
Patient and isolate number
Clinical form/ of lesions
Time between first and second isolations (months)
Condition after first treatment
Drug used in the final retreatment
1 A
CL
6
Reactivation
Pentamidine
1 B
1
2 A
CL
14
Treatment failure
Meglumine antimoniate
2 B
5
3 A
CL
7
Treatment failure
Abandon
3 B
2
4 A
CL
21
Treatment failure
Amphotericin B
4 B
1
5 A
CL
10
Reactivation
Meglumine antimoniate
5 B
6
6 A
CL
5
Reactivation
Meglumine antimoniate
6 B
2
7 A
CL
18
Treatment failure
Anfotericina B
7 B
1
8 A
LC
10
Reactivation
Meglumine antimoniate
8 B
2
9 A
DCL
13
Reactivation
Anfotericina B
9 B
>ten lesions
10 A
CL
13
Reactivation
Anfotericina B
10 B
1
11 A
CL
6
Reactivation
Meglumine antimoniate
11 B
1
12 A
CL
19
Reactivation
Meglumine antimoniate
12 B
2
13 A
CL
10
Reactivation
Meglumine antimoniate
13 B
3
14 A
CL
27
Reactivation
Meglumine antimoniate
14 B
1
15 A
DCL
13
Reactivation
Meglumine antimoniate
15 B
>ten lesions
CL (cutaneous leishmaniasis); DCL (disseminated cutaneous leishmaniasis). Except patient 1 that received 10 mg Sbv/Kg/day on the first treatment, the others received low doses of pentavalent antimony (5 mg Sb/kg/day) with continuous or intermittent schedules or also intralesional injection (patients 4, 5, 6, 7, 10, and 12). All patients were retreated with repetition of the first therapeutic schedules. Five patients (1, 4, 7, 9, and 10) required one-third treatment with drugs of second line.
